| Drug |
Nimesulide is a nonsteroidal anti-inflammatory agent (NSAID) with a usual dose of 100 mg twice per day |
| Goal |
Faster pain relief |
| Challenges |
Increase the rate of drug absorption in a marketed analgesic drug to achieve a rapid onset of action without increasing overall drug exposure |
| Solution |
Utilize Biorise® technology to convert nimesulide into a stabilized, thermodynamically activated state. Several factors contributed to the choice of the HEMA (high-energy mechano-chemical activation) manufacturing process to create a powder that can be formulated into tablets. The drug to polymer ratio is 1:3 (w/w). |
| Data |
A single-dose pharmacokinetic study compared one 100 mg tablet formulated using Biorise technology (activated nimesulide) to one 100 mg of reference product (nonactivated nimesulide) |
